HIV-infection resistance in PMBC-derived dendritic cells modified with recombinant virus

Archives of Virology

Volumn 157, Issue 3, 2012, Pages 413-421

  Xia, Cheng lai ^a   Zhu, Ping ^b   Cai, Yan tao ^c   Zhu, Guang bin ^a   Mei, Zheng rong ^a   Huang, Hanhui ^a   Luo, Di xian ^d   Yan, Peng ke ^a  

^a GUANGZHOU UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Foshan Maternity and Child Health Care Hospital   (China)

^d UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; INTEGRASE; POL PROTEIN; RECOMBINANT PROTEIN; VIRUS RECEPTOR;

ADENOVIRUS; ARTICLE; BIOSYNTHESIS; DENDRITIC CELL; GENE SILENCING; GENE VECTOR; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PATHOGENICITY; VIROLOGY; VIRUS ATTACHMENT; VIRUS REPLICATION;

ADENOVIRIDAE; DENDRITIC CELLS; GENE SILENCING; GENETIC VECTORS; HIV INTEGRASE; HIV-1; HUMANS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECEPTORS, CCR5; RECEPTORS, HIV; RECOMBINANT PROTEINS; VIRUS ATTACHMENT; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857795667     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1185-7     Document Type: Article

References (33)

1. Ardavin C, Martinez DHG, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H (2001) Origin and differentiation of dendritic cells. Trends Immunol 22: 691-700.
2. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 115: 3265-3275.
3. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
4. Cai L, Jiang S (2010) Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem 5: 1813-1824.
5. Chew CB, Potter SJ, Wang B, Wang YM, Shaw CO, Dwyer DE, Saksena NK (2005) Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 33: 206-216.
6. Ferreyra L, Giordano M, Martinez L, Isa MB, Barril P, Masachessi G, Grutadauria S, Pavan J, Nates S (2010) A novel human adenovirus hexon protein of species D found in an AIDS patient. Arch Virol 155: 27-35.
7. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT (2007) Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13: 100-106.
8. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
9. Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, Liu YJ, Lifson JD, Littman DR, Bhardwaj N (2004) Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 78: 5223-5232.
10. Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, Cox KS, Guan L, Long R, Persaud N, Caulfield MJ, Sadoff JC, Emini EA, Thaler S, Shiver JW (2007) Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 23: 67-76.
11. Herbeuval JP, Grivel JC, Boasso A, Hardy AW, Chougnet C, Dolan MJ, Yagita H, Lifson JD, Shearer GM (2005) CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 106: 3524-3531.
12. Hirao LA, Wu L, Satishchandran A, Khan AS, Draghia-Akli R, Finnefrock AC, Bett AJ, Betts MR, Casimiro DR, Sardesai NY, Kim JJ, Shiver JW, Weiner DB (2010) Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther 18: 1568-1576.
13. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC (2009) Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 119: 3544-3555.
14. Jin Q, Marsh J, Cornetta K, Alkhatib G (2008) Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors. J Gen Virol 89: 2611-2621.
15. Kaushik-Basu N, Basu A, Harris D (2008) Peptide inhibition of HIV-1: current status and future potential. Biodrugs 22: 161-175.
16. Kimpton J, Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66: 2232-2239.
17. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, Ko SY, Letvin NL, Haynes BF, Hahn BH, Korber B, Nabel GJ (2009) Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 83: 2201-2215.
18. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
19. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458: 1034-1038.
20. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, Vogelstein B, He TC (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247.
21. Lynch RM, Shen T, Gnanakaran S, Derdeyn CA (2009) Appreciating HIV type 1 diversity: subtype differences in Env. AIDS Res Hum Retroviruses 25: 237-248.
22. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N (2008) HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2, 3-dioxygenase-dependent mechanism. J Clin Invest 118: 3431-3439.
23. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB (2008) Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 14: 1077-1087.
24. Meyers JH, Justement JS, Hallahan CW, Blair ET, Sun YA, O'Shea MA, Roby G, Kottilil S, Moir S, Kovacs CM, Chun TW, Fauci AS (2007) Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS One 2: e458.
25. Pantaleo G, Fauci AS (1996) Immunopathogenesis of HIV infection. Annu Rev Microbiol 50: 825-854.
26. Peterlin BM, Trono D (2003) Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol 3: 97-107.
27. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
28. Potter SJ, Dwyer DE, Saksena NK (2003) Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. Virology 305: 339-352.
29. Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J (2003) Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med 4: 38-47.
30. Schmidt B, Ashlock BM, Foster H, Fujimura SH, Levy JA (2005) HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 343: 256-266.
31. Sung H, Jung YS, Kang MW, Bae IG, Chang HH, Woo JH, Cho YK (2007) High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART. AIDS Res Hum Retroviruses 23: 1223-1229.
32. Vodicka MA, Goh WC, Wu LI, Rogel ME, Bartz SR, Schweickart VL, Raport CJ, Emerman M (1997) Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233: 193-198.
33. Wang YM, Dyer WB, Workman C, Wang B, Peng NK, Lachireddy K, Chew CB, Sullivan J, Saksena NK (2007) Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 5: 235-250.